Chylomicrons

Athens Research

Chylomicrons

9

Lipid Metabolism, Cardiovascular Disease

Research Use Only

Single arc by IEP against antisera to whole human serum. Essentially free of other plasma lipoproteins as determined by electrophoresis using a SPIFE Vis Cholesterol gel kit for lipids and Coomassie Blue for proteins.

Chylomicrons are enterocyte-derived triglyceride-rich lipoproteins that transport dietary lipids from the intestine to peripheral tissues and the liver. These particles (~75–1,200 nm diameter) consist of a hydrophobic core of triglycerides (85–92%) and cholesterol esters, surrounded by a phospholipid monolayer containing apolipoproteins. ApoB-48, synthesized exclusively in the intestine through mRNA editing of the APOB gene, serves as the structural scaffold for chylomicron assembly. During circulation, chylomicrons acquire apoE and apoC-II from HDL, with the latter activating lipoprotein lipase (LPL) to hydrolyze triglycerides into free fatty acids for tissue uptake. Post-lipolysis remnants, enriched in cholesterol and apoE, are cleared by hepatic receptors (LDL-R, LRP1). Familial chylomicronemia syndrome caused by LPL deficiency or mutations in cofactors (apoC-II, GPIHBP1), leading to severe hypertriglyceridemia (more then2,000 mg/dL) and pancreatitis risk. Chylomicron retention disease (CRD), an autosomal recessive SAR1B mutations impair chylomicron secretion, causing vitamin E deficiency, neuropathy, and growth failure. Postprandial chylomicron remnants contribute to atherosclerosis via endothelial dysfunction and proinflammatory pathways. Quantifying apoB-48 provides a specific biomarker for intestinal lipoprotein metabolism, aiding cardiovascular risk stratification.

more then 1 year

Prepared from fresh, non-frozen plasma shown to be non reactive for HBsAg, anti-HCV, anti-HBc, and negative for anti-HIV 1 & 2 by FDA-required tests.

≤ -20° C

41116100